Antonio Marca/iStock via Getty Images
- Phase 1 data on Zymeworks’ (ZYME) ZW191 found that the folate receptor alpha (FRα)-targeting antibody-drug conjugate led to strong anti-tumor activity in ovarian cancer patients that received many prior lines of therapy.
- In the 6.4 mg/kg dose group, the confirmed objective
